Example Page;

Group_1_TA_Agata_Kieliszek_Immune_responses_against_SARS-CoV-2_Presentation_1;

Group_2_TA_Nathan_Roberge_Pathogenesis_and_transmission_of_SARS-CoV-2_Presentation_1;

Group_3_TA_Agata_Kieliszek_Therapeutic_targeting_of_SARS-CoV-2_Presentation_1;

Group_4_TA_Nathan_Roberge_Vaccine_treatment_of_SARS-CoV-2_Presentation_1;

Group_5_TA_Agata_Kieliszek_Stem_cell_models_and/or_therapies_for_SARS-CoV-2_Presentation_1;

Group_6_TA_Nathan_Roberge_Diagnostics_of_SARS-CoV-2_Presentation_1;

Group_1_TA_Agata_Kieliszek_Immune_responses_against_SARS-CoV-2_Presentation_2;

Group_2_TA_Nathan_Roberge_Pathogenesis_and_transmission_of_SARS-CoV-2_Presentation_2;

Group_3_TA_Agata_Kieliszek_Therapeutic_targeting_of_SARS-CoV-2_Presentation_2;

Group_4_TA_Nathan_Roberge_Vaccine_treatment_of_SARS-CoV-2_Presentation_2;

Group_5_TA_Agata_Kieliszek_Stem_cell_models_and/or_therapies_for_SARS-CoV-2_Presentation_2;

Group_6_TA_Nathan_Roberge_Diagnostics_of_SARS-CoV-2_Presentation_2;